Brief: Medincell: Preclinical Studies On Long-Acting Injectable MDC-ANG To Start This Quarter
09/07/2019 17:02
July 9 (Reuters) - Medincell SA MEDCL.PA :
* THIRD LONG-ACTING INJECTABLE ANTIPSYCHOTIC USING MEDINCELL’S TECHNOLOGY ENTERS PRECLINICAL
DEVELOPMENT
* MEDINCELL AND TEVA HAVE SELECTED A LEAD FORMULATION FOR LONG-ACTING INJECTABLE MDC-ANG
* PRECLINICAL STUDIES ARE EXPECTED TO START THIS QUARTER.
Source text for Eikon: ID:nBw7PKc1Ma
Further company coverage: MEDCL.PA
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 09 20;))